

# 1 **Distinct genomic signatures and modifiable risk factors underlying the** 2 **comorbidity between major depressive disorder and cardiovascular disease**

3 Jacob Bergstedt<sup>±,\*</sup>,<sup>1</sup>  
4 Joëlle A. Pasman<sup>±</sup>,<sup>2</sup>  
5 Ziyang Ma<sup>±</sup>,<sup>2</sup>  
6 Arvid Harder<sup>2</sup>  
7 Shuyang Yao<sup>2</sup>,<sup>12</sup>  
8 Nadine Parker<sup>3</sup>  
9 Jorien L. Treur<sup>4</sup>  
10 Dirk J.A. Smit<sup>4</sup>  
11 Oleksandr Frei<sup>3</sup>  
12 Alexey Shadrin<sup>3</sup>  
13 Joeri J. Meijssen<sup>5</sup>  
14 Qing Shen<sup>1,6,7</sup>  
15 Sara Hägg<sup>2</sup>  
16 Per Tornvall<sup>8</sup>  
17 Alfonso Buil<sup>5</sup>  
18 Thomas Werge<sup>5,9,10,11</sup>  
19 Jens Hjerling-Leffler<sup>12</sup>  
20 Thomas D. Als<sup>13</sup>  
21 Anders D. Børghlum<sup>14,15,16</sup>  
22 Cathryn M. Lewis<sup>17,18</sup>  
23 Andrew M. McIntosh<sup>19,20</sup>  
24 Unnur A. Valdimarsdóttir<sup>21,1,22</sup>  
25 Ole A. Andreassen<sup>3,23</sup>  
26 Patrick F. Sullivan<sup>2,24</sup>  
27 Yi Lu<sup>±2</sup>  
28 Fang Fang<sup>±,\*</sup>,<sup>1</sup>

29  
30 <sup>±</sup>Equal contribution

31 <sup>\*</sup>Corresponding authors

32

33 <sup>1</sup> Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

34 <sup>2</sup> Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

35 <sup>3</sup> NORMENT Centre, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo  
36 University Hospital, Oslo, Norway

37 <sup>4</sup> Genetic Epidemiology, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

38 <sup>5</sup> Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark

39 <sup>6</sup> Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, Tongji University School  
40 of Medicine, Shanghai, China

41 <sup>7</sup> Institute for Advanced Study, Tongji University, Shanghai, China

42 <sup>8</sup> Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

43 <sup>9</sup> The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen, Denmark

44 <sup>10</sup> Lundbeck Foundation GeoGenetics Centre, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark

45 <sup>11</sup> Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,  
46 Denmark

47 <sup>12</sup> Department Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden

48 <sup>13</sup> Department of Molecular Medicine (MOMA), Molecular Diagnostic Laboratory, Aarhus University Hospital, Aarhus,  
49 Denmark

50 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

<sup>14</sup> Department of Biomedicine, Aarhus University, Aarhus, Denmark

- 51 <sup>15</sup> The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark  
52 <sup>16</sup>Center for Genomics and Personalized Medicine, Aarhus, Denmark  
53 <sup>17</sup>Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK  
54 <sup>18</sup>Department of Medical and Molecular Genetics, King's College London, London, UK  
55 <sup>19</sup> Centre for Clinical Brain Sciences, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK  
56 <sup>20</sup> Centre for Genomics and Experimental Medicine, University of Edinburgh, Edinburgh, UK  
57 <sup>21</sup> Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland  
58 <sup>22</sup> Department of Epidemiology, Harvard TH Chan School of Public Health, Harvard University, Boston, Massachusetts, USA  
59 <sup>23</sup> K.G. Jebsen Centre for Neurodevelopmental disorders, University of Oslo and Oslo University Hospital, Oslo, Norway  
60 <sup>24</sup>Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, NC, USA  
61

## 62 **Abstract**

63 Major depressive disorder (MDD) and cardiovascular disease (CVD) are often comorbid, resulting in  
64 excess morbidity and mortality. Using genomic data, this study elucidates biological mechanisms, key  
65 risk factors, and causal pathways underlying their comorbidity. We show that CVDs share a large  
66 proportion of their genetic risk factors with MDD. Multivariate genome-wide association analysis of  
67 the shared genetic liability between MDD and atherosclerotic CVD (ASCVD) revealed seven novel loci  
68 and distinct patterns of tissue and brain cell-type enrichments, suggesting a role for the thalamus. Part  
69 of the genetic overlap was explained by shared inflammatory, metabolic, and psychosocial/lifestyle risk  
70 factors. Finally, we found support for causal effects of genetic liability to MDD on CVD risk, but not  
71 from most CVDs to MDD, and demonstrated that the causal effects were partly explained by metabolic  
72 and psychosocial/lifestyle factors. The distinct signature of MDD-ASCVD comorbidity aligns with the  
73 idea of an immunometabolic sub-type of MDD more strongly associated with CVD than overall MDD.  
74 In summary, we identify plausible biological mechanisms underlying MDD-CVD comorbidity, as well  
75 as key modifiable risk factors for prevention of CVD in individuals with MDD.

## 76 Main

77 Major depressive disorder (MDD) and cardiovascular disease (CVD) are highly comorbid<sup>1,2</sup>. Several  
78 mechanisms might explain the observed comorbidity<sup>2</sup>. One explanation is that genetic risk factors for  
79 MDD and CVDs overlap<sup>3,4</sup>. While observed genome-wide genetic correlations between MDD and CVD  
80 are modest<sup>2-4</sup>, this may be because local genetic correlations of opposing directions attenuate  
81 correlations on the genome-wide level, leading to an underestimation of the genetic overlap<sup>5</sup>. The large  
82 polygenicity of MDD<sup>6</sup> might also mask subtypes with stronger genetic relationships to CVD.

83

84 The observed MDD-CVD comorbidity could also be due to non-genetic factors<sup>7</sup>. Cardiovascular risk  
85 factors like high systolic blood pressure, high body mass index (BMI), high levels of low-density  
86 lipoprotein cholesterol, high levels of physical inactivity, presence of type 2 diabetes, and smoking have  
87 all been associated with MDD<sup>8-10</sup>. Moreover, accumulating data show that psychosocial/lifestyle  
88 factors associated with MDD, like low educational attainment, exposure to childhood maltreatment,  
89 loneliness, and atypical sleep patterns, are also important risk factors for CVD<sup>11-14</sup>.

90

91 One common mechanism underlying MDD, CVD, as well as their shared risk factors could be chronic  
92 inflammation. Atherosclerosis, the accumulation of fibrofatty lesions in the arterial wall, is the main  
93 cause of CVD<sup>15</sup>. The build-up of atherosclerotic plaque is a long-term inflammatory process mediated  
94 by immune components in crosstalk with arterial wall cells<sup>16</sup>. Many lines of evidence also support a  
95 role for inflammation in MDD<sup>17</sup>. Excessive or long-term psychosocial stress promote the maturation  
96 and release of inflammatory cytokines like interleukin (IL)-6, which activate the central nervous system  
97 to produce behaviors related to MDD<sup>18</sup>. Importantly, low-grade inflammation, defined by high C-  
98 reactive protein levels, has been observed in more than a quarter of patients with depression<sup>19</sup>,  
99 suggesting the presence of an inflammatory subtype of MDD<sup>20</sup>, which might be especially strongly  
100 associated with CVD.


101

102 The full extent of the genetic overlap between MDD and CVD has not been explored. It remains  
103 unknown if the genetic overlap is associated with specific tissues or brain cell-types, or how this overlap  
104 relates to shared risk factors such as blood pressure, psychosocial/lifestyle traits, metabolic traits, and  
105 inflammation. Moreover, causal effects linking these traits are not fully understood<sup>21-24</sup>.

106

107 Here, we dissect the genetic overlap between MDD and CVD (coronary artery disease, peripheral artery  
108 disease, heart failure, stroke, and atrial fibrillation) by leveraging state-of-the-art genomic data and  
109 methods (Fig. 1). We used newly released summary statistics from a genome-wide association study  
110 (GWAS) of MDD involving 290,000 cases<sup>6</sup>, with substantially increased statistical power compared to  
111 previous GWASs. First, we assessed the pairwise genetic overlap between MDD and CVD on the  
112 genome-wide level, as well as on the level of local partitions of the genome and overlapping causal  
113 variants with MiXeR<sup>25</sup> and LAVA<sup>26</sup>. Using these methods, we were able to consider the direction of  
114 correlation at each locus in the genome, providing a more granular understanding of the genetic overlap  
115 between MDD and CVD. Second, we identified genetic variants and genes that contribute to the shared  
116 liability between MDD and atherosclerotic CVD (ASCVD; coronary artery disease, peripheral artery  
117 disease, heart failure, and stroke) using Genomic Structural Equation Modeling (SEM)<sup>27</sup>. We mapped  
118 identified variants to brain cell-types using novel annotations based on single-cell RNA sequencing in  
119 post-mortem human brain samples<sup>28</sup>. Third, we assessed shared risk factors explaining the association  
120 between MDD and CVD. To do so, we evaluated the polygenic overlap between MDD and well-  
121 established risk factors. We then estimated genetic correlation between MDD and CVD adjusting for  
122 risk factors, and the genetic correlation between the shared genetic liability between MDD and ASCVD

123 and risk factors. Finally, we used Mendelian Randomization (MR) to investigate putative causal effects  
 124 and assess mediation through shared risk factors for MDD and CVD. In brief, this study leverages recent  
 125 large-scale GWAS data and triangulates results from current genomic methods to elucidate etiological  
 126 pathways underlying the comorbidity between MDD and CVD.



127  
 128 **Figure 1.** Graphical abstract illustrating the study approach. The comorbidity between MDD and CVD  
 129 is investigated using genetic and causal inference methods, including assessing overlap with and  
 130 mediation through shared risk factors (metabolic, psychosocial/lifestyle, inflammatory, and blood

131 pressure; Supplementary Table 1). The risk factor group psychosocial/lifestyle is abbreviated to  
132 psychosocial. Created with BioRender.com (license agreements VG26BG3VTL, MK26BG46H3).

## 133 Results


### 134 Most genetic risk factors for CVD overlap with MDD

135 There were weak to moderate genome-wide genetic correlations between MDD and CVDs, as estimated  
136 with linkage disequilibrium score regression (LDSC<sup>29</sup>; Extended Data Fig. 1, Supplementary Table 2).  
137 Information on source GWASs for all traits is given in Supplementary Table 1. The strongest  
138 correlations were noted for peripheral artery disease ( $r_g=0.30$ ,  $SE=0.04$ ,  $P=1\times 10^{-13}$ ), heart failure  
139 ( $r_g=0.29$ ,  $SE=0.03$ ,  $P=1\times 10^{-24}$ ), and coronary artery disease ( $r_g=0.25$ ,  $SE=0.02$ ,  $P=9\times 10^{-45}$ ), while  
140 smaller but statistically significant correlations were observed for stroke and atrial fibrillation ( $r_g=0.18$   
141 and  $r_g=0.11$ ,  $P<1\times 10^{-7}$ ). ASCVDs showed strong correlations among each other, while atrial fibrillation  
142 was only moderately genetically correlated to the ASCVDs (Extended Data Fig. 2a, Supplementary  
143 Table 2). To aid interpretation of these results, we also analyzed specific MDD symptoms. Poor appetite  
144 or overeating was consistently the symptom that showed the strongest genetic correlation to the CVDs  
145 (Extended Data Fig. 1a).

146  
147 We then estimated local genetic correlations between MDD and CVDs in each of 2,495 distinct genomic  
148 regions used in LAVA<sup>26</sup>. The distribution of local genetic correlations is displayed in Fig. 2a, with  
149 points exceeding the horizontal line representing partitions with a genome-wide significant correlation  
150 ( $P_{FDR}<0.05$ ). We found 54 significant local correlations between MDD and CVDs, 40 of which were  
151 for MDD and coronary artery disease. Most significant local correlations were positive (90%), although  
152 results were mixed for peripheral artery disease and heart failure, with 50% and 25% of the partitions,  
153 respectively, showing negative correlations with MDD (Supplementary Table 4). We also investigated  
154 local genetic correlation between MDD and the CVDs in 16 loci in the human leukocyte antigen (HLA)  
155 region (Extended Data Fig 1b). Out of 50 assessed local genetic correlations, 8 were significant,  
156 indicating that this region is a hotspot of genetic correlation between MDD and CVDs.

157  
158 Next, we investigated genetic overlap on the level of risk variants using MiXeR<sup>25</sup> (Supplementary  
159 Tables 5-6). We identified more variants for MDD than for the CVDs, suggesting that MDD is more  
160 polygenic than CVD. To verify these results, we estimated polygenicity using a complementary  
161 Bayesian approach implemented in SBayesS<sup>30</sup>, which showed estimates that were highly correlated  
162 with those of MiXeR (Extended Data Fig. 2b , Supplementary Table 7).

163  
164 Bivariate MiXeR results showed that CVDs shared a large proportion of their causal variants with MDD  
165 (from 64% in atrial fibrillation to 92% in heart failure, Fig. 2b) whereas MDD shared only a small  
166 proportion of its causal variants with CVDs (<20%). Note that for peripheral artery disease the  
167 performance metrics of the model indicate that this finding needs to be interpreted with caution  
168 (Supplementary Table 6). Both shared genetic variants and local genetic correlations exhibit strong  
169 degrees of effect direction concordance (Fig. 2c), suggesting that genetic risk variants for CVDs are  
170 strongly correlated with a genetic subcomponent of MDD.



171  
 172 **Figure 2.** Genetic overlap between MDD and CVD beyond genome-wide genetic correlation. **(a)**  
 173 Volcano plots based on LAVA results showing genomic loci (green dots) with the local genetic  
 174 correlation between MDD and each of the CVDs (x-axis) and the corresponding  $P$ -value (y-axis). Loci  
 175 exceeding the horizontal line are significant at  $P_{FDR} < 0.05$ . Multiple testing was performed separately  
 176 for each trait over all considered loci **(b)** Venn diagrams based on MiXeR results showing the number  
 177 of causal variants that are unique to MDD (left circle), unique to CVD (non-overlapping part of right  
 178 circle), or shared between MDD and CVD (overlapping part of circles). **(c)** Genetic correlation  
 179 estimated by LDSC (x-axis) against the percentage of MDD variants that are shared with the CVD trait  
 180 as estimated by MiXeR (first plot), the percentage of CVD variants that are shared with MDD (second  
 181 plot), and the percentage of CVD variants that are shared with MDD that have concordant effect  
 182 directions (third plot). The fourth plot shows the percentage of local genetic correlations from LAVA  
 183 that have concordant effect directions on the y-axis. **a-c** Sample sizes and information for underlying  
 184 summary statistics GWASs are reported in Supplementary Table 1.  
 185 MDD=Major Depressive Disorder, PAD=Peripheral Artery Disease, CAD=Coronary Artery Disease, AF=Atrial Fibrillation,  
 186 HF=Heart Failure



## 187 **Shared genetic liability to MDD and CVD**

188 To further characterize the genetic overlap, we explicitly modelled the shared liability between MDD  
189 and CVD as a higher-order latent factor using Genomic SEM. We excluded atrial fibrillation because it  
190 deteriorated the model fit (CFI=0.918, SRMR=0.072) and had the lowest factor loading ( $\beta=0.56$ ,  
191 SE=0.05), so that the interpretation of the latent factor changed to representing ASCVD. The final  
192 model had an excellent fit with Comparative Fit Index CFI>0.999 and Standardized Root Mean Squared  
193 Residual SRMR=0.021. The factor loading for MDD was  $\beta=0.32$ . The loadings for the ASCVDs ranged  
194 from  $\beta=0.63$  for stroke (SE=0.06,  $P=4.37\times 10^{-41}$ ) to  $\beta=0.85$  for heart failure (SE=0.07,  $P=2.97\times 10^{-56}$ )  
195 (loadings standardized on the latent factors are shown in Fig. 3a). For comparison, we also fit a latent  
196 factor for the ASCVDs alone (without MDD), which showed similar fit and parameter estimates  
197 (CFI>0.999, SRMR=0.013) (Extended Data Fig. 3a). This shows that shared genetic liability to different  
198 ASCVDs as well as to ASCVDs and MDD (to a lesser extent) can be explained by a single underlying  
199 factor.

200  
201 The GWAS on the latent MDD-ASCVD factor resulted in 205 independent genome-wide significant  
202 loci (Fig. 3b, independent at  $R^2<0.1$  and distance $\geq 250$ kb, Supplementary Table 8). We did not observe  
203 genomic inflation, indicating that results were not strongly affected by population stratification (LDSC  
204 intercept=1.02). Almost three quarters (74.6%) of the genome-wide statistically significant SNPs  
205 showed a high Q heterogeneity, suggesting that their effects were more in line with an independent  
206 pathway than a common pathway model (see methods). Most of this heterogeneity was due to MDD,  
207 as the GWAS for latent ASCVD without MDD showed fewer genome-wide statistically significant  
208 SNPs with a high heterogeneity (30.6%; Extended Data Fig. 3b).

209  
210 For the latent MDD-ASCVD factor, we filtered out variants that showed significant heterogeneity and  
211 considered only variants where the latent MDD-ASCVD factor was the best model for the follow-up  
212 analyses. We retained 72 independent loci underlying the shared genetic liability (Fig. 3b,  
213 Supplementary Table 9). The top SNP after filtering was rs11670056 in the *ELL* gene on chromosome  
214 19, which is part of the transcription elongation factor complex and has previously been associated with  
215 a range of CVDs, blood traits, BMI, and educational attainment (enrichment in associations with other  
216 traits for significant SNPs are shown in Extended Data Fig. 4a). There were 19 top SNPs that were  
217 significant eQTLs for one or multiple genes (top 10 are annotated in Fig. 3b, full results are shown in  
218 Supplementary Table 10). Besides *ELL*, multiple genes on chromosome 10 around *INA* and *CNNM2*  
219 were identified. *INA* is involved in structural neuron regulation whereas *CNNM2* is involved in ion  
220 transportation and has previously been associated with psychiatric as well as cardiovascular traits.

221  
222 From the latent MDD-ASCVD GWAS summary statistics we extracted seven novel loci that were not  
223 among the risk loci in the MDD and ASCVD GWASs that constituted the latent factor (Extended Data  
224 Fig. 4b, Supplementary Table 11). The top SNPs in these loci have not been identified in any GWAS  
225 recorded in the GWAS catalog before, but four of them have shown suggestive associations ( $P<0.05$ )  
226 with metabolic traits (rs11065577, rs11606884, rs2838351, and rs500571).


227  
228 Using partitioned LDSC, we observed that the heritability of the latent MDD-ASCVD factor was  
229 enriched in genes with expression specific to endothelial and blood vessel tissues, which was also  
230 observed for latent ASCVD, but not for MDD (Fig. 3c, Supplementary Table 12). To gain deeper  
231 insights into brain-specific mechanisms, we leveraged high-resolution human brain single-nucleus  
232 RNAseq data<sup>28</sup> and identified four human brain cell-types that exhibited enriched MDD-ASCVD  
233 heritability, including deep layer corticothalamic and 6b cells, midbrain-derived inhibitory neurons,

234 miscellaneous neurons, and vascular cells (Fig. 3d, Supplementary Table 13). Notably, three of the four  
235 cell-types were uniquely associated with the latent MDD-ASCVD factor, displaying no enrichment for  
236 either latent ASCVD without MDD or MDD only, suggesting that the genetic variance for MDD-  
237 ASCVD comorbidity has a distinct functional signature.

238  
239 To externally validate the MDD-ASCVD phenotype, we computed polygenic risk scores (PRS) based  
240 on the summary statistics for the latent MDD-ASCVD factor, as well as for MDD and latent ASCVD,  
241 and found them to significantly predict ASCVD and MDD diagnoses in UK Biobank (UKB) (all  
242  $P < 2 \times 10^{-13}$ ; Supplementary Tables 14-15; note that source and target samples were overlapping and the  
243  $R^2$  values should only be interpreted relative to one another). The PRS for latent ASCVD and the latent  
244 MDD-ASCVD factor explained similar amounts of variance in ASCVD (Fig. 3e). This is in line with  
245 the MiXeR findings (Fig. 2b), suggesting that most causal variants for ASCVD are shared with MDD.  
246 In contrast, as most causal variants for MDD are not shared with ASCVD, the PRS for the latent MDD-  
247 ASCVD factor explained less than half as much variance in MDD as the MDD PRS.

248  
249 Next, we assessed genetic correlations between the latent MDD-ASCVD factor and MDD symptoms.  
250 We found that poor appetite or overeating and suicidal thoughts are the symptoms most strongly  
251 correlated with MDD-ASCVD. In contrast, poor appetite or overeating is among the least genetically  
252 correlated symptoms to MDD (Extended Data Fig. 4c).

253  
254 Finally, we estimated genetic correlation of attention deficit and hyperactivity disorder (ADHD),  
255 anxiety disorders, post-traumatic stress disorder, bipolar disorder, and schizophrenia, with MDD,  
256 MDD-ASCVD, and ASCVD. We found that ADHD, anxiety disorder, and PTSD were genetically  
257 correlated with ASCVD (Extended Data Fig. 4d). In addition, PTSD and ADHD showed similar genetic  
258 correlations for MDD and MDD-ASCVD, which might suggest that the variants that are common to  
259 MDD and ASCVD explain most of the genetic correlation between MDD and these disorders.



260  
 261 **Figure 3.** Shared genetic liability factor for MDD-ASCVD. **(a)** Latent factor model as specified in  
 262 Genomic SEM with the ‘observed’ variables in rectangles and the latent variables in circles. Factor  
 263 loadings (standardized on the latent factors) are given in black and variances in blue. Sample sizes for  
 264 underlying GWAS summary statistics are reported in Supplementary Table 1 **(b)** Latent MDD-ASCVD  
 265 factor GWAS results. The x-axis shows genomic position, and the y-axis shows statistical significance  
 266 as  $-\log_{10}(P)$ . Genome-wide significant SNPs that were filtered out because of significant heterogeneity  
 267  $Q_{SNP}$  are displayed in grey. The top 10 eQTL genes are displayed with dashed vertical lines indicating  
 268 their position. **(c)** Enrichment results in GTEX tissues for the latent MDD-ASCVD factor, with latent  
 269 ASCVD (without MDD) and MDD-only as comparison. **(d)** Enrichment results for the latent MDD-  
 270 ASCVD factor, latent ASCVD, and MDD-only in brain cell types. **(e)** Proportion of variance explained  
 271 in MDD and CVD phenotypes in the UKB (defined using ICD-codes listed in Supplementary Table 14)  
 272 by each of 3 PRSs for the latent MDD-ASCVD factor, latent ASCVD, or MDD-only. **c, d** Enrichment  
 273 is measured using significance testing in a two-sided t-test displayed as  $-\log_{10}(P)$ . Only tissues with a  
 274 significant association ( $P_{FDR} < 0.05$ ) are shown. Multiple testing was performed over tested tissues/cell-  
 275 types.

276 MDD=Major Depressive Disorder; MDD-ASCVD=common factor for MDD and ASCVD; ASCVD=common factor for the  
277 atherosclerotic cardiovascular diseases

## 278 **Polygenic overlap between MDD and risk factors**


279 Next, we aimed to identify risk factors that contribute to the genetic and phenotypic association between  
280 MDD and CVD. First, we assessed the genome-wide genetic correlations between MDD and risk  
281 factors. Confirming previous findings, we observed strong to moderate genetic correlations of MDD  
282 with psychosocial/lifestyle factors, such as loneliness ( $r_g=0.68$ ,  $SE=0.02$ ), childhood maltreatment  
283 ( $r_g=0.55$ ,  $SE=0.02$ ), and exercise ( $r_g=-0.33$ ,  $SE=0.02$ ) (Fig. 5, Extended Data Fig. 6). Among metabolic  
284 factors, MDD showed the strongest genetic correlation with type II diabetes ( $r_g=0.19$ ,  $SE=0.018$ ),  
285 followed by levels of high-density lipoprotein cholesterol ( $r_g=-0.14$ ,  $SE=0.01$ ) and triglycerides  
286 ( $r_g=0.18$ ,  $SE=0.02$ ). MDD showed weak but statistically significant genetic correlations with other  
287 metabolic factors (i.e., BMI, non-high-density lipoprotein, low-density lipoprotein, and total  
288 cholesterol) ( $r_g<0.15$ ). We observed significant genetic correlations for MDD with the inflammatory  
289 markers IL-6 ( $r_g=0.22$ ,  $SE=0.06$ ) and C-reactive protein ( $r_g=0.15$ ,  $SE=0.02$ ). We did not observe genetic  
290 correlation of MDD with blood pressure traits. As a comparison, for CVDs, the largest genetic  
291 correlations were found between heart failure and BMI ( $r_g=0.55$ ,  $SE=0.03$ ) and type II diabetes ( $r_g=0.49$ ,  
292  $SE=0.03$ ) (Extended Data Fig. 5, Supplementary Table 2). Results for MDD symptoms largely followed  
293 the pattern of MDD diagnosis, although changed appetite showed stronger genetic correlations with  
294 metabolic factors than did MDD diagnosis (Extended Data Fig. 6, Supplementary Table 3).

295  
296 Causal variant and local genetic correlation analysis revealed several distinct patterns of polygenic  
297 overlap between MDD and risk factors. We found that psychosocial/lifestyle factors, childhood  
298 maltreatment, and BMI showed similar levels of polygenicity to MDD (Extended Data Fig. 2b,  
299 Supplementary Tables 5 and 7). In addition, they exhibited a large degree of shared variants and many  
300 local genetic correlations with MDD (Fig. 4a, Extended Data Fig. 7, Supplementary Tables 4 and 6).  
301 Out of these factors, loneliness and childhood maltreatment also showed high levels of effect direction  
302 concordance (93% and 73% of shared causal variants and 85% and 75% of significant local genetic  
303 correlations for loneliness and childhood maltreatment were in the same direction; Fig. 4b, correlation  
304 coefficients are shown in Supplementary Tables 4 and 6). Combined with high polygenicity, such  
305 concordance translates to large genome-wide genetic correlations. In contrast, educational attainment,  
306 smoking, exercise, physical activity, BMI, and sleep duration had similar levels of polygenicity and a  
307 large degree of polygenic overlap with MDD, but low effect direction concordance, suggesting that  
308 genome-wide genetic correlations underestimate the polygenic overlap with MDD for these traits.

309  
310 Genetic factors for blood pressure traits showed unique patterns of polygenic overlap in that they were  
311 polygenic (>5,000 causal variants; Extended Data Fig. 2b) but did not overlap strongly with genetic risk  
312 factors for MDD (<0.30 of risk variants overlapping; Fig. 4a). Moreover, risk variants that did overlap  
313 showed low degree of effect direction concordance (48%-57% of shared variants in the same direction;  
314 Fig. 4b). We observed 97 significant local genetic correlations for the three blood pressure traits, 60%  
315 of which were positive. These findings suggest that MDD and blood pressure share variants that exhibit  
316 both positive and negative correlations, which are cancelled out in the genome-wide estimate.

317  
318 Type II diabetes, lipid traits, and C-reactive protein showed low polygenicity (<2,500 causal risk  
319 variants). Total cholesterol, non-high-density lipoprotein, and low-density lipoprotein did not share the  
320 majority of their risk variants with MDD, and shared variants showed low degrees of effect direction  
321 concordance. However, like the CVDs, type II diabetes, triglyceride levels, and C-reactive protein levels  
322 shared most of their risk variants with MDD, and these variants showed high degrees of concordance

323 (>85% of shared variants in the same direction). High-density lipoprotein shared most of its risk variants  
 324 with MDD, in consistently opposite directions.



325  
 326 **Figure 4.** Local and causal-variant level genetic correlations between MDD and risk factors. The legend  
 327 is shared among all panels. (a) Venn diagrams based on MiXeR results showing the number of causal  
 328 variants that are unique to MDD (left circle), the risk factor (non-overlapping part of right circle) or  
 329 shared between MDD and the risk factor (overlapping part of circles). (b) Genome-wide genetic  
 330 correlation estimated by LDSC (rg, x-axis) against the percentage of MDD causal variants that are  
 331 shared with the risk factor as estimated by MiXeR (top left), the percentage of risk factor causal variants  
 332 that are shared with MDD (top right), the percentage of risk factor causal variants that are shared with  
 333 MDD that have concordant effect directions (bottom left). The bottom right plot shows the percentage



334 of local genetic correlations from LAVA that have concordant effect directions on the y-axis.  
335 Cardiovascular traits are also shown for comparison. **a, b** Standard errors for MiXeR, LAVA, and LDSC  
336 results are reported in Supplementary Tables 2-6. Sample sizes for GWAS summary statistics are  
337 reported in Supplementary Table 1. Note that IL6 was excluded from MiXeR results because it failed  
338 performance checks (see methods).

339 Psychosocial=Psychosocial/Lifestyle; PAD=Peripheral Artery Disease, CAD=Coronary Artery Disease, AF=Atrial  
340 Fibrillation, HF=Heart Failure, DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure;  
341 Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes;  
342 TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol;  
343 LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein;

#### 344 **Risk factors explain part of the genetic correlation between MDD and CVD**


345 To assess the degree to which risk factors explain the genetic overlap between MDD and CVD, we  
346 estimated genetic correlations adjusted for risk factors (individually or as a group) using Genomic SEM  
347 (Fig. 5a; results per individual risk factor are shown in Extended Data Fig. 8 and Supplementary Table  
348 Table 16). The largest reduction in point estimate was observed for the genetic correlation between  
349 MDD and peripheral artery disease after adjustment for the group of psychosocial/lifestyle factors,  
350 indicating that these risk factors explain much of the genetic correlation between MDD and peripheral  
351 artery disease. Similarly, the genetic correlation between MDD and coronary artery disease, as well as  
352 the latent CVD factor, were attenuated after adjusting for psychosocial/lifestyle factors. The reduction  
353 was mainly driven by loneliness (Extended Data Fig. 8). Genetic correlations of MDD with peripheral  
354 artery disease and stroke were no longer significant after adjusting for psychosocial/lifestyle factors.  
355 We also observed some attenuation in the genetic correlation between MDD and CVD after adjusting  
356 for childhood maltreatment, metabolic factors, or inflammatory markers, although confidence intervals  
357 overlapped.

358  
359 Next, we specified the risk factors as mediators instead of covariates in the Genomic SEM model and  
360 compared the path estimates from MDD to CVD. Observing attenuation in the association between  
361 MDD and CVD when a risk factor is modelled as a mediator rather than a covariate supports the  
362 interpretation that the risk factor mediates some of the link between MDD and CVD. For all  
363 psychosocial/lifestyle factors together, the inflammation traits, and for type II diabetes, the 95%  
364 confidence intervals did not overlap between the mediator and covariate models, suggesting that these  
365 risk factors are mediating part of the link between MDD and CVD (Supplementary Table 17).

366  
367 Finally, we estimated genetic correlations between the risk factors and the latent MDD-ASCVD factor  
368 (Fig. 5b) and found that the latent MDD-ASCVD factor was substantially more genetically correlated  
369 with blood pressure traits, C-reactive protein levels, and metabolic factors than MDD only, suggesting  
370 that these factors characterize the genetic liability to MDD-ASCVD rather than to MDD alone.

371

372



373  
374

**Figure 5.** Genome-wide correlations between MDD and risk factors. **(a)** Genetic correlation between MDD and CVD before and after adjustment for groups of risk factors (color coded). **(b)** Comparison of genetic correlation between MDD (dark green) and the latent CVD-ASMDD factor (lilac) and individual risk factors. **a, b** Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1.

Psychosocial=Psychosocial/Lifestyle; MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

### 385 Causal pathways linking MDD and CVD

386 We investigated putatively causal relationships between MDD and CVD using two-sample MR. Results  
387 from the inverse variance-weighted (IVW) estimator are presented in Fig. 6a-c (full results including  
388 sensitivity analyses Supplementary Table 18). Instruments were Steiger filtered, i.e., SNPs explaining  
389 significantly more variance in the outcome than the exposure were excluded. The results provide  
390 support for a causal effect of MDD liability on all CVDs, with the strongest effects observed for  
391 coronary and peripheral artery disease. There was no statistically significant pleiotropy for the CVD  
392 outcomes, and the results were consistent across weighted median, mode, and Egger sensitivity  
393 analyses, providing support for the IVW estimates. Concerning risk factors, we observed no support for  
394 a causal effect of MDD liability on levels of blood pressure, physical activity, sleep duration, or IL6.  
395 However, increased liability to MDD was associated with increased risk of loneliness, smoking, type II  
396 diabetes, and levels of C-reactive protein (Fig. 6a). The results were again consistent across sensitivity  
397 analyses. There was statistically significant pleiotropy between MDD and triglycerides, rendering this  
398 effect uninterpretable. The average instrument strength of MDD was  $F=33$ . Heterogeneity across  
399 instruments was statistically significant for most outcomes, suggesting variable effects (Supplementary  
400 Table 18).

401

402 We also investigated the potential causal effect in the other direction with genetic instruments to CVDs  
403 and risk factors as exposures and MDD as outcome (Fig. 6b). We provide evidence for a statistically  
404 significant causal effect of stroke, loneliness, smoking, exercise, educational attainment, childhood  
405 maltreatment, high-density lipoprotein, and BMI on MDD risk (Fig. 6b), which was robust across the  
406 sensitivity analyses. No robust effects were observed for other CVDs, blood pressure, other metabolic  
407 traits, or inflammatory markers.


408  
409 When using genetic instruments for the latent MDD-ASCVD factor to predict the risk factors,  
410 statistically significant effects were observed for pulse pressure and type II diabetes (Extended Data  
411 Fig. 9c). There was statistically significant pleiotropy only for systolic blood pressure. There were small  
412 effects on BMI, childhood maltreatment, educational attainment, high-density lipoprotein, exercise,  
413 loneliness, and smoking, but these were less robust across sensitivity analyses (Supplementary Table  
414 18). For most outcomes, there was statistically significant instrument heterogeneity.

415  
416 We extended univariable results with multivariable MR to assess if there was support for causal effects  
417 of MDD on CVD explained by the risk factors. We included only risk factors that were statistically  
418 significantly predicted by MDD in the univariable MR analysis. Fig. 6c shows that, as in the Genomic  
419 SEM analyses, the effect of MDD on CVD was attenuated after adjusting for groups of risk factors,  
420 although confidence intervals were wide. Results for individual risk factors are shown in Extended Data  
421 Fig. 10 and Supplementary Table 19. The effect of MDD liability on peripheral artery disease, heart  
422 failure, stroke, and atrial fibrillation risk was no longer statistically significant after adjusting for the  
423 groups of metabolic or psychosocial/lifestyle factors, although the confidence intervals overlapped with  
424 those from the unadjusted estimates. Likewise, the effect of MDD on atrial fibrillation was no longer  
425 statistically significant after adjusting for childhood maltreatment. In Fig. 6d we show a schematic  
426 overview of results from all MR analyses.

427  
428 To investigate possible bias due to sample overlap, we repeated the main IVW analyses using MDD  
429 summary statistics based on GWAS excluding the UKB sample (the main source of overlap). We  
430 observed small differences in the estimates, but the interpretation remained the same for all results  
431 (Extended Data Fig. 9a-b, Supplementary Table 20). Furthermore, we repeated the analyses using  
432 Latent Heritable Confounder (LHC) MR, which is robust to sample overlap<sup>31</sup>. The results pattern was  
433 similar, although the point estimates were slightly attenuated for CVD risk (e.g., no longer statistically  
434 significant for heart failure and atrial fibrillation) and became stronger for most other traits (Extended  
435 Data Fig. 9c). We conclude that although sample overlap impacted the point estimates, the interpretation  
436 of results remained similar.

437





438  
 439 **Figure 6.** Results from univariable and multivariable MR (IVW estimates). **(a)** Effect of liability to  
 440 MDD (exposure) on CVD and risk factors (outcomes). **(b)** Effects in the opposite direction with MDD  
 441 as outcome and CVD and risk factors as exposures. **(c)** Effects of MDD on CVD while adjusting for  
 442 groups of risk factors in multivariable MR. **(d)** Schematic overview of levels of evidence for causal  
 443 effects, with solid lines indicating convincing evidence (consistent across sensitivity analyses) for such  
 444 effects, and dashed lines indicating evidence for some of the relationships tested within the trait  
 445 categories. The arrows from the risk factors to the association between MDD and the CVDs indicate  
 446 that the combined risk factors attenuated the association so that it was no longer statistically significant.  
 447 **a-d** Points and error bars represent regression coefficients and 95% CIs. Sample sizes for GWAS  
 448 summary statistics are reported in Supplementary Table 1. The term beta refers to the log odds ratio.

449 \* Indicates that the observed statistically significant association suffered from pleiotropy; possible  
 450 causal effect should not be interpreted.

451 Psychosocial=Psychosocial/Lifestyle; MDD=Major Depressive Disorder; MDD-ASCVD=common factor for CVD and MDD  
 452 and ASCVD; PAD=Peripheral Artery Disease; HF=Heart Failure; STR=Stroke; CAD=Coronary Artery Disease; AF=Atrial

453 Fibrillation; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment;  
454 Phys. Act.=Physical activity; Child. Mal.= Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-  
455 Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein;  
456 IL6=Interleukin-6; CRP=C-Reactive Protein; MR=Mendelian randomization IVW=Inverse Variance Weighted.

## 457 Discussion

458 Here, we showed that genetic risk factors for CVD overlap strongly with MDD. We modeled the shared  
459 genetic liability between MDD and ASCVD as a latent factor and showed that, distinct from MDD  
460 alone, it is associated with gene expression specific to thalamic and vascular cell-types in the brain and  
461 is genetically correlated with immunometabolic factors and blood pressure. Further, we showed that the  
462 association between MDD and CVD is partly explained by modifiable risk factors and provide evidence  
463 that it is likely causal in nature.

464  
465 In line with previous results<sup>32-35</sup> we found weak to moderate genome-wide genetic correlations between  
466 MDD and CVDs. Analysis on the level of shared risk variants showed that MDD was substantially  
467 more polygenic than the CVD traits and that most risk variants for CVD were in fact shared with MDD  
468 and had concordant effect directions. In addition, we found many positive local genetic correlations  
469 between MDD and CVD, especially for coronary artery disease although that might reflect the fact that  
470 the coronary artery disease GWAS have substantially larger effect sample size than the GWASs of the  
471 other CVDs. Interestingly, we found that the *HLA* region was a hotspot for local genetic correlation  
472 between MDD and CVDs. These findings suggest that genetic overlap between MDD and CVD is  
473 underestimated in genome-wide correlation analyses.

474  
475 We modelled the shared liability between MDD and ASCVD as a latent factor and performed a GWAS  
476 on the factor. Atrial fibrillation deteriorated the fit of the latent factor and it was therefore excluded.  
477 This was in line with results that showed that atrial fibrillation was substantially less genetically  
478 correlated with the ASCVDs than they were with each other. Combined, these results suggest that atrial  
479 fibrillation and ASCVDs have partly distinct sources of genetic variation. We identified many loci for  
480 MDD-ASCVD, some of which were uniquely associated with the shared liability and not with the  
481 constituent traits. We found that heritability for the MDD-ASCVD latent factor was enriched for genes  
482 specifically expressed in vascular braincells, deep layer corticothalamic 6b (projecting to the thalamus),  
483 and midbrain-derived inhibitory neurons (predominantly located in the thalamus). This cell-type  
484 enrichment signature was not found for MDD or ASCVD alone, suggesting that a distinct mechanism  
485 involving thalamic circuits underlies the shared liability to MDD-ASCVD. Altered thalamic function  
486 has indeed been implicated previously in CVD<sup>36-38</sup> and MDD<sup>39,40</sup>, and white matter integrity in thalamic  
487 radiations show associations with aortic area and myocardial wall thickness, suggesting that it has a role  
488 in the 'heart-brain' connection<sup>41</sup>.

489  
490 MDD showed a high degree of genetic overlap with risk factors. We showed that MDD was  
491 substantially more polygenic than blood pressure traits, lipid traits, and C-reactive protein. In contrast,  
492 psychosocial/lifestyle traits were equally polygenic to MDD and showed a large degree of overlap with  
493 MDD. Interestingly, the local and variant-level analysis indicated that blood pressure traits shared a  
494 substantial proportion of their risk variants with MDD (in line with a previous report<sup>42</sup>), which was  
495 masked at the genome-wide level due to their opposing effect directions. Similarly, BMI and lipid traits  
496 showed discordant effect directions to MDD in overlapping risk variants as well as opposite directions  
497 in local genetic correlations. Finally, C-reactive protein shared almost three quarters of its risk variants  
498 with MDD, most of which were in the positive direction, indicating a genetic relationship between C-  
499 reactive protein and MDD that was masked by the large polygenicity of MDD. Overall, these findings

500 refine our understanding of the polygenic overlap between MDD and risk factors shared between MDD  
501 and CVD, and indicate that it is stronger and more complex than has previously been reported.

502  
503 We estimated genome-wide genetic correlations between MDD and CVD adjusting for risk factors and  
504 found that psychosocial/lifestyle factors explain a substantial part of the genetic correlation between  
505 MDD and CVD and highlight loneliness as an important factor in the relationship between MDD and  
506 CVD.

507  
508 We found that, compared to MDD, the latent MDD-ASCVD factor was characterized by genetic  
509 correlations with immunometabolic factors and blood pressure, suggesting that the shared genetic  
510 liability to MDD and ASCVD is associated with an immunometabolic subtype of depression. The  
511 existence of an immunometabolic subtype of depression has been proposed previously, based on a long  
512 line of evidence of oxidative stress and neuroendocrine and inflammatory dysregulation in MDD, that  
513 are preferentially associated with atypical symptoms of MDD (e.g., weight gain and oversleeping)<sup>43</sup>.  
514 Indeed, we find that poor appetite or overeating is the MDD symptom with the consistently greatest  
515 genetic correlations to the CVDs, and it is among the most genetically correlated with MDD-ASCVD,  
516 while it is among the least correlated symptoms to MDD, although confidence intervals were too wide  
517 to be conclusive. We did not find large genetic correlations between sleep duration measured using an  
518 accelerometer over one week and the MDD-ASCVD factor. However, statistically significant variants  
519 for the MDD-ASCVD factor were strongly enriched in statistically significant variants for self-reported  
520 short sleep duration (<6 hours per night)<sup>44</sup> suggesting that short sleep duration is more related to MDD-  
521 ASCVD comorbidity than overall sleep duration.

522  
523 Mental disorders that are highly comorbid with MDD, such as psychotic disorders, anxiety disorders  
524 and PTSD, have also been shown to be associated with CVD<sup>45</sup>. We find that ADHD, anxiety disorders  
525 and PTSD show genetic correlations with ASCVD and MDD-ASCVD. For ADHD and PTSD, the  
526 genetic correlation was similar between MDD and MDD-ASCVD. Future work should estimate latent  
527 factors representing shared and distinct sources of genetic covariance between MDD, ADHD, anxiety  
528 disorders, and PTSD and investigate how those factors relate to ASCVD.

529  
530 We found robust support for the likelihood of causal effects of MDD on CVD. Previous two-sample  
531 MR studies have observed associations between genetic liability to MDD and risk of coronary artery  
532 disease but results for risk of heart failure have been inconsistent<sup>32,33,46,47</sup>. Another study found an effect  
533 of genetic liability to MDD on risk of stroke<sup>48</sup>. Using more recent GWAS data, we confirmed an effect  
534 of genetic liability to MDD on coronary artery disease and stroke and found robust associations for  
535 heart failure and peripheral artery disease.

536  
537 Except for stroke, we found limited evidence for a causal effect of CVDs on MDD, which is contrary  
538 to literature suggesting that such effects exist<sup>24</sup>. The MDD sample is mainly based on large volunteer-  
539 based studies that might select against individuals with CVD. Indeed, participants in the UKB study are  
540 healthier than the general population<sup>49</sup>. In addition, interpretation of the MR estimate in this case is  
541 complicated by the fact that CVD is a time-varying exposure with late age-of-onset<sup>50</sup>. However, we do  
542 find that genetic instruments capture the well-established association between stroke and subsequent  
543 MDD<sup>51</sup>. Therefore, the findings in our study offer some indication that the association between CVDs  
544 and subsequent MDD might have been overestimated in previous studies, possibly due to reverse  
545 causation, surveillance bias, or unmeasured confounding.

546

547 We observed effects of genetic liability to MDD on most of the risk factors. We did not observe  
548 associations between genetic liability to MDD and blood pressure traits, although the presence of  
549 correlated and anti-correlated genetic components complicates interpretation. Indeed, using genetic  
550 instruments for the latent MDD-ASCVD factor, we did observe strong associations for pulse pressure.  
551 Previous MR studies of the association of C-reactive protein and IL-6 levels with MDD risk have also  
552 shown inconsistent results<sup>52,53</sup>. We did not find an effect of genetic instruments for inflammatory  
553 markers on MDD. However, we did find associations between genetic liability to MDD and increased  
554 C-reactive protein levels, lipid levels, and type II diabetes, offering evidence that MDD might lead to  
555 long-term dysregulated immunometabolic pathways<sup>43</sup>. Likewise, in line with previous evidence<sup>54</sup>, we  
556 provided support for a causal effect of liability to MDD on smoking, which, in turn, can lead to  
557 inflammation. These results are in line with results based on genetic covariance estimated from all  
558 genetic variants that tentatively supported a mediating role for C-reactive protein and IL6 levels in the  
559 association between MDD and ASCVD.

560  
561 Analyzing risk factors explaining the effect of genetic liability to MDD on CVDs, we observed that  
562 only the association between genetic liability to MDD and coronary artery disease remained statistically  
563 significant after adjusting for psychosocial/lifestyle or metabolic covariates in a multivariable MR  
564 analysis. In addition, we found that smoking status attenuates the association between genetic liability  
565 to MDD and peripheral artery disease, for which smoking is a particularly strong risk factor<sup>55</sup>.  
566 Interestingly, we find that loneliness is an equally important factor explaining the relationship between  
567 MDD and peripheral artery disease, as well as heart failure, which is in line with the results from the  
568 adjusted genome-wide genetic correlation analysis discussed above. This emphasizes the need for  
569 interventions and preventive policies for reducing loneliness in the population, which has a further  
570 increased prevalence during the COVID-19 pandemic and has been described as a pandemic itself<sup>56,57</sup>.

571  
572 For most CVDs, no risk factor group could fully explain the genetic association between MDD and the  
573 CVD. This suggests that there are other mechanisms at work as well, which are not captured by the  
574 genetic data used in the study. For instance, GWAS measure lifetime genetic risk (up to the point of the  
575 maximum age in the sample) and cannot capture dynamic processes of cumulative and interactive risk.  
576 Relatedly, the statistical genetic tools we employed cannot formally distinguish between mediation and  
577 covariation pathways. Future studies should triangulate our findings using longitudinal observational  
578 and experimental data. Follow-up studies could also investigate the out-of-sample predictive power and  
579 clinical usefulness of polygenic risk scores for the shared liability to MDD-ASCVD, and evaluate their  
580 ability to identify individuals at risk for immunometabolic depression, as we could not investigate this  
581 due to sample overlap in the present study. Another limitation is that the bivariate MiXeR model was  
582 not able accurately estimate the polygenic overlap between MDD and IL6. The likely reason the MiXeR  
583 model failed in this case is because the two traits have very different genetic architectures with MDD  
584 being highly polygenic and IL6 being the least polygenic of the traits in the study, combined with the  
585 low sample size of the IL6 GWAS. In addition, to assess generalizability, these findings should be  
586 replicated with data from different ancestry sources. The lack of large genetic datasets from non-  
587 European populations is a crucial limitation that is widely acknowledged and yet difficult to circumvent.  
588 Observational studies have shown that MDD and CVDs could demonstrate different associations  
589 depending on ancestry<sup>58,59</sup>, and more genetic and non-genetic research is needed to understand such  
590 differences.

591  
592 To our knowledge, this is the first study moving beyond bivariate genetic overlap to investigate the  
593 latent genetic liability shared between MDD and ASCVD. Our triangulation of genome-wide, local,  
594 and variant-level methods provides compelling evidence that MDD and CVD, and their shared risk

595 factors are more strongly overlapping genetically than has previously been reported. Similarly, using  
596 genome-wide, variant-level, and genetic instrument methods we show how shared risk factors explain  
597 the likely causal association between MDD and CVD. For both MDD and CVDs, we have used updated  
598 GWAS summary statistics, with an up to 3-fold increase in sample size compared to previous reports  
599 <sup>32-35</sup>.

600  
601 This study dissected the architecture of polygenic overlap between MDD and CVD, and their shared  
602 risk factors to elucidate mechanisms linking these comorbid diseases. Our findings suggest that the  
603 shared genetic liability to MDD and ASCVD has a distinct genomic signature compared to MDD or  
604 any CVD separately. Moreover, the shared genetic liability shows stronger genetic correlations with  
605 immunometabolic risk factors than MDD alone, in line with the idea of an inflammatory<sup>60</sup> or  
606 immunometabolic<sup>43</sup> subtype of MDD especially associated with atherosclerotic CVDs, highlighting the  
607 role of inflammation in MDD-ASCVD comorbidity. Indeed, we found that the HLA region is a hotspot  
608 of local genetic correlation between MDD and the CVD traits, that genetic liability to MDD is  
609 associated with C-reactive protein levels, and tentative support that inflammatory markers mediate  
610 some of the link between MDD and ASCVD. We highlight loneliness and smoking as important targets  
611 for intervention to reduce the risk of MDD and CVD, as well as CVD in individuals with MDD.  
612 Building on this work, tools can be developed to identify individuals at risk for developing  
613 immunometabolic depression (e.g., using blood tests of high-density lipoprotein and C-reactive protein  
614 levels) and target them for cholesterol-lowering or anti-inflammatory medical interventions.



615

## 616 **Methods**

### 617 **Data sources**

618 All data sources were summary statistics from the largest and most recent GWAS to date (see  
619 Supplementary Table 1). The MDD symptoms GWAS have not been published, although they have  
620 been used in other publications<sup>61</sup>. The symptom GWASs were based on Patient Health Questionnaire  
621 (PHQ-9) items measured in the UKB, that captures most, but not all, core symptoms of MDD, and were  
622 published online<sup>62</sup>. The disease trait GWASs were mostly based on electronic health record diagnoses.  
623 The physical activity and sleep duration traits were measured in the UKB using an accelerometer over  
624 a one-week period<sup>63</sup>.

625

626 The summary statistics were cleaned using the `cleansumstats` pipeline  
627 (<https://github.com/BioPsykc/cleansumstats>). SNPs were aligned and harmonized against reference data.  
628 Analyses were conducted on the TSD cluster, maintained by the University of Oslo, using singularity  
629 containers. Containers are packaged applications with their environmental dependencies that are used  
630 to standardize analyses across different sites, ensuring correct software versions and parameters<sup>64</sup>. All  
631 GWAS studies were ethically approved and were conducted in compliance with ethical guidelines.  
632 Ethics approval for the UK-Biobank study was given by the North West Centre for Research Ethics  
633 Committee (11/NW/0382). The work described here was approved by UK-Biobank under application  
634 number 22224.

### 635 **Genetic overlap**

#### 636 *Genome-wide genetic correlation*

637 To assess shared liability between MDD, CVD, MDD symptoms, and risk factors, we estimated genetic  
638 overlap on a genome-wide, polygenic, and local level. First, for the genome-wide level, we estimated  
639 genetic correlation between each of the traits using LD score regression (LDSC<sup>29</sup>). We excluded the  
640 human leukocyte antigen (*HLA*) region from the main analysis because its complex LD structure can  
641 bias both heritability and genetic correlation results<sup>65</sup>. However, a sensitivity analysis including the *HLA*  
642 region showed very similar results to the main analysis (not shown). Note that LDSC performs well in  
643 the presence of sample overlap.

#### 644 *Local genetic correlation*

645 We used Local Analysis of (co)Variant Association (LAVA<sup>26</sup>) to assess genetic correlation in regions  
646 of the genome. We assessed local genetic correlation in 2,495 genomic regions that cover the autosomes  
647 and have been defined to minimize LD between the regions, while simultaneously keeping the regions  
648 approximately equal in size. These regions are provided with the LAVA software package. We only  
649 considered local genetic correlation in loci where both traits showed marginally significant heritability  
650 ( $P < 0.05$ ). For these loci, we adjusted local genetic correlation  $P$ -values for multiple testing using the  
651 Benjamini-Hochberg method. This adjustment was done separately for all pairs of traits considered. To  
652 match the results from LDSC and MiXeR, we excluded the *HLA* region from the main analyses. For  
653 local genetic correlation between MDD and the CVD traits, we performed an additional analysis in the  
654 *HLA* region.

#### 655 *Polygenic overlap*

656 To investigate polygenic overlap beyond genetic correlation, we used MiXeR v1.3<sup>25</sup> to assess the  
657 number of shared and distinct non-zero genetic variants between MDD and another trait required to

658 explain at least 90% of heritability in the two traits, referred to as ‘causal’ variants. Because it assesses  
659 overlap regardless of the effect direction of each variant, it gives a more adequate picture of localized  
660 correlations that could cancel each other out when estimating the genome-wide genetic correlation. We  
661 excluded the *HLA* region, following the software recommendations<sup>25</sup>. A sensitivity analysis of genetic  
662 overlap between MDD and the CVD traits including the *HLA* region showed very similar results to the  
663 main analysis (not shown). To assess stability of point estimates and estimate their standard deviations,  
664 we fitted the MiXeR model 20 different times for 2 million randomly selected SNPs with minor allele  
665 frequency of at least 5%. The number of 20 runs follows recommendations published previously<sup>66</sup>. The  
666 averaged results were then plotted in Venn diagrams to visualize the polygenic overlap. The MiXeR  
667 model was evaluated for each trait using by 1) comparing the AIC of the univariate MiXeR model with  
668 the LDSC model, which does not include a parameter to directly estimate polygenicity (Supplementary  
669 Table 5); 2) comparing the AIC of the bivariate MiXeR model with the AIC of the model with the least  
670 possible amount of polygenic overlap required to explain observed genetic correlation; 3) comparing  
671 the AIC of the bivariate MiXeR model with the AIC of the model with maximum amount of polygenic  
672 overlap (in such a model, all risk variants of the least polygenic trait are also risk variants of the other  
673 trait), and finally 4); evaluating the stability of the point estimates over the 20 runs (Supplementary  
674 Table 6). These metrics have been described in detail previously<sup>66</sup>. Except for the univariate test, the  
675 MiXeR model failed these checks for IL6, which was therefore excluded from the results. The MiXeR  
676 model performed poorly for the IL6 likely because it is a trait with low polygenicity and was measured  
677 in a relatively small sample (Extended Data Fig. 2, Supplementary Table 1).

678

679 To complement the univariate polygenicity analysis in MiXeR, we estimated polygenicity in a Bayesian  
680 model implemented in SBayesS<sup>30</sup>. We used a 15,000 sample MCMC chain with a 5,000-sample burn-  
681 in. The SBayesS methods did not converge for peripheral artery disease, possibly due to lower number  
682 of cases in the GWAS.

### 683 **Shared liability to MDD and ASCVD**

684 To move beyond bivariate association to multivariate overlap, we conducted factor analysis on MDD  
685 and the CVDs using Genomic SEM<sup>27</sup> to assess if genetic latent factors could explain the genetic  
686 covariance between the traits. Genomic SEM uses LDSC to estimate the genetic covariance matrix and  
687 uses that in a SEM framework to identify multivariate relationships in the data. A Comparative Fit Index  
688  $CFI > .90$ , Standardized Root Mean Square Residual  $SRMR < .03$ , and standardized factor loadings  $\beta > 0.3$   
689 were set as criteria for acceptable model fit. The best model fit was found for a factor with coronary  
690 artery disease, peripheral artery disease, heart failure, and stroke as indicators, which we interpret as a  
691 genetic factor for ASCVD. To model a genetic factor for shared liability to MDD and ASCVD, we  
692 defined a higher-order factor with this ASCVD factor plus MDD as indicators. The standardized loading  
693 of the first indicator (coronary artery disease) was set to 1. The residual variance of the ASCVD factor  
694 was forced to be 0, so that all variance was forced into the MDD-ASCVD factor. For comparison, we  
695 also estimated a common factor model for ASCVD without MDD, which is visualized in Extended Data  
696 Fig. 3a.

697

698 Subsequently, we conducted a summary statistics-based GWAS on the MDD-ASCVD second-order  
699 latent factor to identify variants associated with this latent liability. We used the package-default  
700 diagonally weighted least squares estimator (DWLS). To derive genome-wide significant independent  
701 loci we used the plink clumping procedure as implemented in FUMA<sup>67</sup>, with  $R=0.6$  and distance=250  
702 kb, and reference data from 1000 genomes. To assess the heterogeneity of the SNP effects, we also fit  
703 an independent pathway model for each SNP, where each indicator was regressed on the SNP directly  
704 instead of forcing the effect through the latent factor. We compare the common pathway  $\chi_{SNP}^{2,com}$  to the

705 independent pathway  $\chi_{\text{SNP}}^{2,\text{ind}}$  to derive  $Q_{\text{SNP}}$ . For our follow-up analyses, we filtered out all SNPs that  
706 had effects that were more consistent with an independent pathway model at  $P_{Q_{\text{SNP}}} < 0.05$ . This stringent  
707 procedure filters out SNPs with heterogeneous effects on MDD and the ASCVD factor. This way,  
708 variants are excluded that should be considered risk variants for MDD or CVDs separately rather than  
709 risk variants for MDD-ASCVD.

710  
711 Using FUMA, we checked if genome-wide significant SNPs for the MDD-ASCVD factor were  
712 enriched in genome-wide significant SNPs for traits in the GWAS-catalog. Then, to define unique loci,  
713 we overlaid the independent genomic risk loci (now clumped at  $R^2=0.1$  and 3000 kb window) for MDD-  
714 ASCVD with the risk loci for the constituent traits (MDD, peripheral artery disease, coronary artery  
715 disease, heart failure, and stroke). We used the ‘intersect’ function in bedtools to see if the risk regions  
716 were overlapping. If they were independent (according to the clump criteria) they were regarded as  
717 novel loci. We also identified genes whose regulation is significantly impacted by the top significant  
718 SNPs to interpret the biological implications of our findings. For this, we use eQTL estimates from  
719 FUMA based on PsychENCODE reference data<sup>68</sup>. Using the same procedures (though without filtering  
720 out heterogeneous SNPs) we conducted a GWAS for the the ASCVD genetic factor.

721  
722 To externally validate the latent MDD-ASCVD GWAS results, we computed PRS using LDpred2  
723 (automatic mode with HapMap3 reference data). We compared the MDD-ASCVD PRS with a PRS  
724 based on MDD only, and with a PRS based on latent CVD without MDD. As a target sample we used  
725 the UKB. Summary statistics for ASCVD traits excluding the UKB were unavailable, and we chose to  
726 leave the UKB in for all traits. Sample overlap is likely to lead to overfitting, resulting in an inflation  
727 of explained variance. However, this is less of a concern when comparing PRS among themselves,  
728 rather than assessing absolute predictive value. As target phenotypes, we extracted CVD and MDD  
729 cases according to healthcare registry ICD codes from data field 41270 (see Supplementary Table 12).  
730 We used logistic regression analysis to predict case status from each PRS while controlling for the first  
731 10 principal components for ancestry, sex, and year of birth. Continuous variables were standardized  
732 and centered. We estimated Nagelkerke’s  $R^2$  to capture explained variance in the disease traits.

### 733 **Tissue and cell-type analysis**

734 To gain insight into the biological mechanisms underlying the common liability to MDD and ASCVD,  
735 we performed a tissue and cell-type analysis using partitioned LDSC. Cell-type identification was based  
736 on the top decile of specifically expressed genes (referred to as top decile expression proportion [TDEP]  
737 genes). The methodology has been described extensively in previous studies<sup>69-71</sup>.

738  
739 We identified TDEP genes for brain cell-types from single-nucleus RNA-seq data measured in  
740 dissections of three adult human post-mortem brain samples for the Adult Human Brain Atlas<sup>28</sup>, part of  
741 the Human Cell Atlas. We used the manually annotated 31 superclusters and 461 clusters provided by  
742 the atlas<sup>28</sup>. We considered a curated set of 18,090 protein-coding autosomal genes, excluding those in  
743 the *HLA* region (because the method relies on LDSC), with expression in at least one of the 461 cell-  
744 clusters.

745  
746 To establish TDEP genes for 16 human tissues, we utilized bulk RNA-seq data from GTEx v8<sup>72</sup>. In  
747 line with previous research, we removed tissues with <100 donors and non-natural tissues (e.g., cell  
748 lines) as well as testis tissues (expression outlier)<sup>69</sup>. Prior to analysis in partitioned LDSC, we expanded  
749 the boundaries of TDEP genes by 100kb to include possible enhancers or promoters.

750



751 We tested the associations between GWAS traits and tissue/cell-types by investigating heritability  
752 enrichment within the TDEP genes for each tissue/cell-type. To ensure that annotation enrichment could  
753 not be better explained by other overlapping annotations, we adjusted for enrichment in 53 previously  
754 defined baseline LDSC annotations (LDSC v1.0.1) of coding, UTR, promoter, intronic, various  
755 enhancers, histone marks and other epigenetic marks, genomic regions<sup>71</sup>.

## 756 **Pathways of association between MDD and CVD**

### 757 *Mediation in Genomic SEM*

758 We employed several different techniques to assess whether the association between MDD and CVD  
759 could be explained by shared risk factors. First, we estimated the genome-wide genetic correlations  
760 adjusting for the effects of risk factors using Genomic SEM. To aid interpretation, we added the  
761 covariates in groups, controlling for all trait groups separately (psychosocial/lifestyle, childhood  
762 maltreatment, metabolic, or inflammation traits; see Supplementary Table 1). We only included traits  
763 in the covariate groups that showed significant genome-wide genetic correlation with MDD. Note that  
764 we did not adjust for blood pressure traits, since none of the blood pressure traits showed genome-wide  
765 significant correlation with MDD. Attenuation of genetic correlation after adjustment was taken to  
766 indicate that shared risk factors account for some (or all) of the association between MDD and CVD.  
767

768 Next, we modeled the risk factors explicitly as mediators in Genomic SEM. If the direct effect is  
769 attenuated in the mediation model as compared to the covariate model, we view this as tentative support  
770 for the existence of mediation (following procedures suggested by the software developers<sup>73</sup>). Note  
771 however that this interpretation relies on untestable assumptions. Finally, we also tested the effects of  
772 individual risk factors (both as covariates and mediators) instead of grouping them.

### 773 *Univariable and multivariable Mendelian randomization*

774 To test if the associations between MDD and CVD and risk factors were causal, we used Mendelian  
775 Randomization (MR). We assessed the effects of MDD on the CVDs and risk factors, the effect of the  
776 CVDs and risk factors on MDD, and the effect of latent MDD-ASCVD on risk factors. MR uses genetic  
777 variants as instrumental variables to assess the presence of causal effects of an ‘exposure’ on an  
778 ‘outcome’. Core assumptions include that the instrumental variables are robustly associated with  
779 exposure and are not associated with the outcome (other than through the effect from exposure) or  
780 unmeasured confounders. We used the inverse variance weighted (IVW) estimate in the two-sample  
781 MR R-package<sup>74</sup> as our main estimate. As instrument SNPs, we selected independent GWAS hits at  
782  $P < 5 \times 10^{-8}$ ,  $R^2 < 0.001$ , and distance  $< 5\text{Mb}$ . In the analysis of the effect of genetic instruments of  
783 peripheral artery disease, physical activity, childhood maltreatment, and IL6 on MDD risk, we allowed  
784 instruments with higher  $P$ -values to be able to reach a total of 10 instruments ( $P < 1e-5$ ). For the MDD-  
785 ASCVD exposure, we used SNPs that showed no significantly heterogenous effects in the Genomic  
786 SEM model ( $Q_{\text{pval}} > .05$ , see above), in order to limit the possibility of pleiotropic effects of this, by  
787 nature, heterogenous instrument.  
788

789 We performed several sensitivity analyses to test and adjust for violation of MR assumptions. All  
790 analyses were Steiger filtered, meaning that all SNPs that explained significantly more variance in the  
791 outcome than the exposure were excluded as instruments<sup>75</sup>. Weighted median and mode regression were  
792 used to correct for effect size outliers that could represent pleiotropic effects<sup>76</sup>. MR-Egger regression  
793 was used to assess pleiotropy (pleiotropy leads to a significant intercept) and correct for it (unless  $I^2$   
794 indicated NOME violation of the NO Measurement Error [NOME] assumption, in which case we did  
795 not report MR-Egger results<sup>77,78</sup>). Second, to assess the strength of our instruments, we used Cochran’s  
796  $Q$  to assess heterogeneity in the SNP effects<sup>79</sup> and the  $F$ -statistic to control for weak instrument bias<sup>80</sup>.

797 Third, we performed sensitivity analyses to gauge the effect of sample overlap in the GWASs that were  
798 used. Although sample overlap has been suggested to not greatly impact MR results when the source  
799 GWASs have a large sample size and the overlap is limited<sup>81</sup>, we wanted to ensure sample overlap did  
800 not lead to bias in our findings. We assessed the genetic covariance intercepts for all MDD-trait pairs  
801 from the LDSC analyses and observed that most were more than 1 SD away from 0, indicating that  
802 sample overlap was present (Supplementary Table 2). We repeated the analyses with MDD summary  
803 statistics leaving out the UKB sample, which is the sample responsible for most of the overlap and  
804 compared the results. Also, we repeated the analyses using Latent Heritable Confounder MR (LHC-  
805 MR<sup>31</sup>), which aims to correct for the presence of unmeasured heritable confounders as well as sample  
806 overlap.

807

808 Subsequently, we test the adjusted pathways using multivariable MR (MVMR) analyses. The difference  
809 with the mediation test in Genomic SEM is that we now use instrumental variables that corroborate a  
810 causal interpretation. Because MVMR relies on simple regression analysis, it cannot formally test  
811 mediation; instead, the causal estimate is adjusted for the risk factor. To support a directional  
812 interpretation, we included only risk factors as mediators that were significantly affected by MDD  
813 according to the univariable analysis results. In MVMR, only an IVW estimate can be derived. Steiger  
814 filtering was performed on the exposure-outcome association. These analyses were not replicated in  
815 LHC, which does not accommodate multivariable analyses. For ease of interpretation, we again grouped  
816 the mediators and adjusted for all mediators in a group concurrently. We only included a mediator in a  
817 group if it was significant in the univariate analysis. Additionally, we performed analyses adjusting for  
818 single mediators. We selected instruments for each variable in a model by a clumping step with the  
819 same parameters as in the univariate MR case ( $P < 5 \times 10^{-8}$ ,  $R^2 < 0.001$ ). We then combined instruments  
820 for all variables in a model into a single set of instruments and performed another clumping step with  
821 the same parameters. These instruments were then aligned to the same effect allele. We estimated the  
822 effect of genetic liability to MDD on CVD traits adjusting for covariates using multivariate MR with  
823 the MVMR R-package<sup>82</sup>.

## 824 **Data availability**

825 Links to download publicly available published GWAS summary statistics data used as inputs in this  
826 study are listed in Supplementary Table 1. Single nucleus RNA sequencing data in the adult human  
827 brain can be found at <https://github.com/linnarsson-lab/adult-human-brain>. Researchers can request  
828 access to the UK-Biobank data resources at [https://www.ukbiobank.ac.uk/enable-your-research/apply-  
829 for-access](https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access); data for PRS analysis described in this study were accessed under accession number 22224.  
830 Gene expression data from human tissues can be found at <https://www.gtexportal.org/home/datasets>.  
831 Summary statistics for MDDCVD are available upon request.

## 832 **Code availability**

833 Code used for processing and analyzing data in this work will be uploaded to  
834 <https://github.com/jacobbergstedt>. Code for singularity containers can be found at  
835 <https://github.com/comorment>.

## References

- 836 1. Han, X. *et al.* Disease trajectories and mortality among individuals diagnosed with depression: a  
837 community-based cohort study in UK Biobank. *Mol Psychiatry* **26**, 6736–6746 (2021).
- 838 2. Nemeroff, C. B. & Goldschmidt-Clermont, P. J. Heartache and heartbreak—the link between  
839 depression and cardiovascular disease. *Nat Rev Cardiol* **9**, 526–539 (2012).
- 840 3. Kendler, K. S., Gardner, C. O., Fiske, A. & Gatz, M. Major Depression and Coronary Artery  
841 Disease in the Swedish Twin Registry. *Arch Gen Psychiatry* **66**, 857 (2009).
- 842 4. Xian, H. *et al.* Genetic vulnerability and phenotypic expression of depression and risk for ischemic  
843 heart disease in the Vietnam era twin study of aging. *Psychosom Med* **72**, 370–5 (2010).
- 844 5. Zhang, F., Cao, H. & Baranova, A. Shared Genetic Liability and Causal Associations Between  
845 Major Depressive Disorder and Cardiovascular Diseases. *Front Cardiovasc Med* **8**, (2021).
- 846 6. Als, T. D. *et al.* Depression pathophysiology, risk prediction of recurrence and comorbid  
847 psychiatric disorders using genome-wide analyses. *Nat Med* **29**, 1832–1844 (2023).
- 848 7. Raynor, D. A., Pogue-Geile, M. F., Kamarck, T. W., McCaffery, J. M. & Manuck, S. B.  
849 Covariation of Psychosocial Characteristics Associated With Cardiovascular Disease: Genetic and  
850 Environmental Influences. *Psychosom Med* **64**, 191–203 (2002).
- 851 8. Vaccarino, V. *et al.* Depression and coronary heart disease: 2018 position paper of the ESC  
852 working group on coronary pathophysiology and microcirculation. *Eur Heart J* **41**, 1687–1696  
853 (2020).
- 854 9. Penninx, B. W. J. H. Depression and cardiovascular disease: Epidemiological evidence on their  
855 linking mechanisms. *Neurosci Biobehav Rev* **74**, 277–286 (2017).
- 856 10. Roth, G. A. *et al.* Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update  
857 From the GBD 2019 Study. *J Am Coll Cardiol* **76**, 2982–3021 (2020).
- 858 11. Fan, M. *et al.* Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a  
859 prospective study of 385 292 UK biobank participants. *Eur Heart J* **41**, 1182–1189 (2020).
- 860 12. Valtorta, N. K., Kanaan, M., Gilbody, S., Ronzi, S. & Hanratty, B. Loneliness and social isolation  
861 as risk factors for coronary heart disease and stroke: systematic review and meta-analysis of  
862 longitudinal observational studies. *Heart* **102**, 1009–16 (2016).
- 863 13. Suglia, S. F. *et al.* Childhood and Adolescent Adversity and Cardiometabolic Outcomes: A  
864 Scientific Statement From the American Heart Association. *Circulation* **137**, (2018).
- 865 14. Schultz, W. M. *et al.* Socioeconomic Status and Cardiovascular Outcomes: Challenges and  
866 Interventions. *Circulation* **137**, 2166–2178 (2018).
- 867 15. Libby, P. *et al.* Atherosclerosis. *Nat Rev Dis Primers* **5**, 56 (2019).
- 868 16. Libby, P. *et al.* Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic  
869 of the Week. *J Am Coll Cardiol* **72**, 2071–2081 (2018).
- 870 17. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary  
871 imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).
- 872 18. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary  
873 imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).
- 874 19. Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B. & Khandaker, G. M. Prevalence of low-grade  
875 inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol Med*  
876 **49**, 1958–1970 (2019).
- 877 20. Suneson, K., Lindahl, J., Chamli Hårsmar, S., Söderberg, G. & Lindqvist, D. Inflammatory  
878 Depression-Mechanisms and Non-Pharmacological Interventions. *Int J Mol Sci* **22**, (2021).
- 879 21. Carney, R. M. & Freedland, K. E. Depression and coronary heart disease. *Nat Rev Cardiol* **14**,  
880 145–155 (2017).

- 881 22. Lu, Y., Wang, Z., Georgakis, M. K., Lin, H. & Zheng, L. Genetic Liability to Depression and Risk  
882 of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes. *J Am*  
883 *Heart Assoc* **10**, (2021).
- 884 23. Li, G. H.-Y. *et al.* Evaluation of bi-directional causal association between depression and  
885 cardiovascular diseases: a Mendelian randomization study. *Psychol Med* **52**, 1765–1776 (2022).
- 886 24. Hare, D. L., Toukhsati, S. R., Johansson, P. & Jaarsma, T. Depression and cardiovascular disease:  
887 a clinical review. *Eur Heart J* **35**, 1365–1372 (2014).
- 888 25. Frei, O. *et al.* Bivariate causal mixture model quantifies polygenic overlap between complex traits  
889 beyond genetic correlation. *Nat Commun* **10**, 2417 (2019).
- 890 26. Werme, J., van der Sluis, S., Posthuma, D. & de Leeuw, C. A. An integrated framework for local  
891 genetic correlation analysis. *Nat Genet* **54**, 274–282 (2022).
- 892 27. Grotzinger, A. D. *et al.* Genomic SEM Provides Insights into the Multivariate Genetic  
893 Architecture of Complex Traits. *Nat Hum Behav* 305029 (2018).
- 894 28. Siletti, K. *et al.* Transcriptomic diversity of cell types across the adult human brain. *Science (1979)*  
895 **382**, (2023).
- 896 29. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in  
897 genome-wide association studies. *Nat Genet* **47**, 291 (2015).
- 898 30. Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex traits.  
899 *Nat Genet* **50**, 746–753 (2018).
- 900 31. Darrous, L., Mounier, N. & Kutalik, Z. Simultaneous estimation of bi-directional causal effects  
901 and heritable confounding from GWAS summary statistics. (2020)  
902 doi:10.1101/2020.01.27.20018929.
- 903 32. Zhang, F., Cao, H. & Baranova, A. Shared Genetic Liability and Causal Associations Between  
904 Major Depressive Disorder and Cardiovascular Diseases. *Front Cardiovasc Med* **8**, (2021).
- 905 33. Li, G. H.-Y. *et al.* Evaluation of bi-directional causal association between depression and  
906 cardiovascular diseases: a Mendelian randomization study. *Psychol Med* **52**, 1765–1776 (2022).
- 907 34. Torgersen, K. *et al.* Shared genetic loci between depression and cardiometabolic traits. *PLoS*  
908 *Genet* **18**, e1010161 (2022).
- 909 35. Hagenaaers, S. P. *et al.* Genetic comorbidity between major depression and cardio-metabolic traits,  
910 stratified by age at onset of major depression. *American Journal of Medical Genetics Part B:*  
911 *Neuropsychiatric Genetics* **183**, 309–330 (2020).
- 912 36. Wei, H.-L. *et al.* Disrupted resting-state functional connectivity of the thalamus in patients with  
913 coronary heart disease. *Heliyon* **9**, e13423 (2023).
- 914 37. Rosen, S. D. Silent Ischemia as a Central Problem: Regional Brain Activation Compared in Silent  
915 and Painful Myocardial Ischemia. *Ann Intern Med* **124**, 939 (1996).
- 916 38. Rosen, S. D. *et al.* Central nervous pathways mediating angina pectoris. *The Lancet* **344**, 147–150  
917 (1994).
- 918 39. Greicius, M. D. *et al.* Resting-State Functional Connectivity in Major Depression: Abnormally  
919 Increased Contributions from Subgenual Cingulate Cortex and Thalamus. *Biol Psychiatry* **62**,  
920 429–437 (2007).
- 921 40. Paul, E. R., Östman, L., Heilig, M., Mayberg, H. S. & Hamilton, J. P. Towards a multilevel model  
922 of major depression: genes, immuno-metabolic function, and cortico-striatal signaling. *Transl*  
923 *Psychiatry* **13**, 171 (2023).
- 924 41. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic resonance  
925 images. *Science* **380**, abn6598 (2023).
- 926 42. Torgersen, K. *et al.* Shared genetic loci between depression and cardiometabolic traits. *PLoS*  
927 *Genet* **18**, e1010161 (2022).



- 928 43. Milaneschi, Y., Lamers, F., Berk, M. & Penninx, B. W. J. H. Depression Heterogeneity and Its  
929 Biological Underpinnings: Toward Immunometabolic Depression. *Biol Psychiatry* **88**, 369–380  
930 (2020).
- 931 44. Dashti, H. S. *et al.* Genome-wide association study identifies genetic loci for self-reported habitual  
932 sleep duration supported by accelerometer-derived estimates. *Nat Commun* **10**, 1100 (2019).
- 933 45. Shen, Q. *et al.* Psychiatric disorders and subsequent risk of cardiovascular disease: a longitudinal  
934 matched cohort study across three countries. *EClinicalMedicine* **61**, 102063 (2023).
- 935 46. Tang, B., Yuan, S., Xiong, Y., He, Q. & Larsson, S. C. Major depressive disorder and  
936 cardiometabolic diseases: a bidirectional Mendelian randomisation study. *Diabetologia* **63**, 1305–  
937 1311 (2020).
- 938 47. Lu, Y., Wang, Z., Georgakis, M. K., Lin, H. & Zheng, L. Genetic Liability to Depression and Risk  
939 of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes. *J Am*  
940 *Heart Assoc* **10**, (2021).
- 941 48. Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis provide insights  
942 into the pathogenesis of heart failure. *Nat Commun* **11**, 163 (2020).
- 943 49. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK  
944 Biobank Participants With Those of the General Population. *Am J Epidemiol* **186**, 1026–1034  
945 (2017).
- 946 50. Morris, T. T. *et al.* Interpretation of Mendelian randomization using a single measure of an  
947 exposure that varies over time. *Int J Epidemiol* **51**, 1899–1909 (2022).
- 948 51. Taylor, W. D., Aizenstein, H. J. & Alexopoulos, G. S. The vascular depression hypothesis:  
949 mechanisms linking vascular disease with depression. *Mol Psychiatry* **18**, 963–74 (2013).
- 950 52. Kappelmann, N. *et al.* Dissecting the Association Between Inflammation, Metabolic  
951 Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample  
952 Mendelian Randomization Study. *JAMA Psychiatry* **78**, 161–170 (2021).
- 953 53. Khandaker, G. M. *et al.* Shared mechanisms between coronary heart disease and depression:  
954 findings from a large UK general population-based cohort. *Mol Psychiatry* **25**, 1477–1486 (2020).
- 955 54. Wootton, R. E. *et al.* Evidence for causal effects of lifetime smoking on risk for depression and  
956 schizophrenia: a Mendelian randomisation study. *Psychol Med* **50**, 2435–2443 (2020).
- 957 55. Behrooz, L., Abumoawad, A., Rizvi, S. H. M. & Hamburg, N. M. A modern day perspective on  
958 smoking in peripheral artery disease. *Front Cardiovasc Med* **10**, 1154708 (2023).
- 959 56. Office of the Surgeon General (OSG). *Our Epidemic of Loneliness and Isolation: The U.S.*  
960 *Surgeon General’s Advisory on the Healing Effects of Social Connection and Community.* (2023).
- 961 57. Ernst, M. *et al.* Loneliness before and during the COVID-19 pandemic: A systematic review with  
962 meta-analysis. *American Psychologist* **77**, 660–677 (2022).
- 963 58. González, H. M. & Tarraf, W. Comorbid cardiovascular disease and major depression among  
964 ethnic and racial groups in the United States. *Int Psychogeriatr* **25**, 833–841 (2013).
- 965 59. Watkins, D. C., Assari, S. & Johnson-Lawrence, V. Race and Ethnic Group Differences in  
966 Comorbid Major Depressive Disorder, Generalized Anxiety Disorder, and Chronic Medical  
967 Conditions. *J Racial Ethn Health Disparities* **2**, 385–394 (2015).
- 968 60. Felger, J. C. & Miller, A. H. Identifying Immunophenotypes of Inflammation in Depression:  
969 Dismantling the Monolith. *Biol Psychiatry* **88**, 136–138 (2020).
- 970 61. Kappelmann, N. *et al.* Dissecting the Association Between Inflammation, Metabolic  
971 Dysregulation, and Specific Depressive Symptoms. *JAMA Psychiatry* **78**, 161 (2021).
- 972 62. Howrigan, D. P. *et al.* Nealelab/UK\_Biobank\_GWAS: v2. (2023)  
973 doi:10.5281/ZENODO.8011558.
- 974 63. Doherty, A. *et al.* GWAS identifies 14 loci for device-measured physical activity and sleep  
975 duration. *Nat Commun* **9**, 5257 (2018).

- 976 64. Akdeniz, B. C. *et al.* COGEDAP: A COmprehensive GENomic Data Analysis Platform. *arXiv:*  
977 *2212.14103* (2022).
- 978 65. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression  
979 that maximizes the potential of summary level GWAS data for SNP heritability and genetic  
980 correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
- 981 66. Hindley, G. *et al.* Charting the Landscape of Genetic Overlap Between Mental Disorders and  
982 Related Traits Beyond Genetic Correlation. *Am J Psychiatry* **179**, 833–843 (2022).
- 983 67. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and  
984 annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 985 68. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the human  
986 brain. *Science (1979)* **362**, (2018).
- 987 69. Bryois, J. *et al.* Genetic identification of cell types underlying brain complex traits yields insights  
988 into the etiology of Parkinson’s disease. *Nat Genet* **52**, 482–493 (2020).
- 989 70. Skene, N. G. *et al.* Genetic identification of brain cell types underlying schizophrenia. *Nat Genet*  
990 **50**, 825–833 (2018).
- 991 71. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide  
992 association summary statistics. *Nat Genet* **47**, 1228–1235 (2015).
- 993 72. Aguet, F. *et al.* The GTEx Consortium atlas of genetic regulatory effects across human tissues.  
994 *Science (1979)* **369**, 1318–1330 (2020).
- 995 73. Nivard, M. Mediation model in GenomicSEM.  
996 <https://gist.github.com/MichelNivard/04bf4ddcf3c32f905175de3058ca967a> (2018).
- 997 74. Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in  
998 Mendelian randomization studies. *Hum Mol Genet* **27**, R195–R208 (2018).
- 999 75. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely  
1000 measured traits using GWAS summary data. *PLoS Genet* **13**, e1007081 (2017).
- 1001 76. Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian  
1002 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* **46**, 1985–1998 (2017).
- 1003 77. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments:  
1004 effect estimation and bias detection through Egger regression. *Int J Epidemiol* **44**, 512–525 (2015).
- 1005 78. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian  
1006 randomization analyses using MR-Egger regression: the role of the I<sup>2</sup> statistic. *Int J Epidemiol* **45**,  
1007 1961–1974 (2016).
- 1008 79. Bowden, J., Hemani, G. & Davey Smith, G. Invited Commentary: Detecting Individual and Global  
1009 Horizontal Pleiotropy in Mendelian Randomization—A Job for the Humble Heterogeneity  
1010 Statistic? *Am J Epidemiol* **187**, 2681–2685 (2018).
- 1011 80. Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian randomization  
1012 studies. *Int J Epidemiol* **40**, 755–764 (2011).
- 1013 81. Mounier, N. & Kutalik, Z. Bias correction for inverse variance weighting Mendelian  
1014 randomization. *Genet Epidemiol* **47**, 314–331 (2023).
- 1015 82. Sanderson, E., Spiller, W. & Bowden, J. Testing and correcting for weak and pleiotropic  
1016 instruments in two-sample multivariable Mendelian randomization. *Stat Med* **40**, 5434–5452  
1017 (2021).
- 1018
- 1019

## 1020 **Acknowledgments**

1021 This work was supported by European Union's Horizon 2020 Research and Innovation Programme  
1022 (CoMorMent project; Grant #847776). JAP was supported by the the US National Institutes of Mental Health  
1023 (R01MH123724). NP was supported by the Marie Skłodowska-Curie Actions Grant 801133 (Scientia  
1024 fellowship) and RCN 300309. JLT is supported by a European Research Council (ERC) Starting grant  
1025 (UNRAVEL-CAUSALITY, grant number 101076686) and by Foundation Volksbond Rotterdam. CML is  
1026 part-funded the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS  
1027 Foundation Trust and King's College London. AMM is supported by the Wellcome Trust (220857/Z/20/Z)  
1028 and UKRI (MR/W014386/1). ADB was supported by grants from the Lundbeck Foundation (R102-A9118,  
1029 R155-2014-1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, "CoCA"), NIH/NIMH  
1030 (1R01MH124851-01). OA was supported by the European Union's Horizon 2020 research and innovation  
1031 program (grant agreement No 847776 and 964874), Research Council of Norway (223273, 296030, 326813).  
1032 PFS gratefully acknowledges support from the Swedish Research Council (Vetenskapsrådet, award  
1033 D0886501), the US National Institutes of Mental Health (R01s MH124871, MH121545, and MH123724),  
1034 and the Horizon 2020 Programme of the European Union (grant agreement No 847776). LY was supported  
1035 by the European Research Council (grant agreement ID 101042183). The authors acknowledge HERMES  
1036 and CARDIoGRAMplusC4D consortia for contributing data and guidance. The PRS analyses have been  
1037 conducted using the UK-Biobank Resource under Application Number 22224. They were enabled by  
1038 resources in project sens2017519 provided by the National Academic Infrastructure for Supercomputing in  
1039 Sweden (NAISS) at UPPMAX, funded by the Swedish Research Council through grant agreement no. 2022-  
1040 06725. This work was performed on Services for Sensitive Data, University of Oslo, with resources provided  
1041 by UNINETT Sigma2, the national infrastructure for high performance computing and data storage in  
1042 Norway.



## 1043 **Author contributions**

1044 This study was conceived by JB, PFS, YL, and FF. It was supervised by YL and FF. JB, JAP, and ZM were  
1045 responsible for the main analyses, visualization, and the drafting of the manuscript. AH performed the tissue  
1046 expression analyses with help and supervision from SY, JHL, and PFS, who also helped with the writing  
1047 and interpretation of these results. NP was involved in providing and cleaning GWAS summary statistic  
1048 data. DJAS supervised the Genomic SEM analysis and JLT the MR analyses. OF and AS were involved in  
1049 providing the containerized software used in this project and supervising the MiXeR analyses. JJM, QS, SH,  
1050 PT, AB, and TW contributed to interpreting findings. CML, AMM, TDA, and ADB were responsible for  
1051 the MDD GWAS summary statistics and were involved in the interpretation of findings. SH helped with  
1052 UKB data access and curation for the PRS analyses. SH, UVA, OA, PFS, YL and FF provided suggestions  
1053 and expert supervision and contributed to the writing. All authors have read and provided feedback on the  
1054 manuscript.

## 1055 **Competing interests**

1056 CML sits on the SAB of Myriad Neuroscience and has received speaker/consultancy fees from SYNLAB  
1057 and UCB. OAA is a consultant to Cortechs.ai, and has received speaker's honoraria from Lundbeck, Janssen  
1058 and Sunovion. PFS has received consulting fees from and is a shareholder of Neumora therapeutics. Other  
1059 authors declare no competing interests.

1060





**Extended Data Fig. 1 | Genetic correlation of MDD and MDD symptoms with CVDs.**

(a) Results are based on LD Score Regression analysis. Points and error bars represent genetic correlation and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. (b) Local genetic correlation between MDD and CVDs in 16 loci in the HLA region. Only loci with marginally significant local heritability for both traits are shown. Points above the vertical line are significant based on multiple testing adjustment for considered loci performed for each CVD trait separately.

MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease






1064 **Extended Data Fig. 2 | Genetic correlation and polygenicity for MDD, CVD, and risk factors.**

1065 **(a)** Heatmap of the genetic correlations between MDD, the CVDs, and the risk factors, with the color indicating the  
1066 effect direction (negative: red, positive: blue) and the size and shade of the square illustrating the size of the  
1067 correlation. Results are based on LD Score Regression analysis. **(b)** Estimates of number of non-zero variants for  
1068 from SBayesS for each trait (y-axis) and estimates of non-zero variants required to explain 90% of trait heritability  
1069 for each trait from MiXeR (x-axis) for MDD, the CVDs, and the risk factors. Note that for PAD polygenicity  
1070 estimates did not converge for SBayesS, possibly because of few number of cases.

1071 MDD=Major Depressive Disorder; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery  
1072 Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical  
1073 activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-  
1074 High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein


1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077



1078


**Extended Data Fig. 3 | Common latent factor underlying atherosclerotic CVD.**

(a) Latent atherosclerotic CVD (ASCVD) model, defined by stroke, peripheral artery disease (PAD), heart failure (HF), and coronary artery disease (CAD). All ‘observed’ traits are based on GWAS summary statistics. Results are from confirmatory factor analysis in Genomic SEM, and standardized factor loadings are given for each path. Circular dashed arrows give the trait variance. (b) Manhattan plot of the GWAS on ASCVD, with each dot representing a SNP with its position on the x-axis and its  $P$ -value on the y-axis. Genome-wide significant SNPs with a significant heterogeneity  $Q_{SNP}$  (with a strong effect on one or some of the indicators that was not well explained through the common latent factor) are displayed in grey. The dashed line indicates the genome-wide significance threshold ( $P < 5e-8$ ).



1080 **Extended Data Fig. 4 | The genomic signature of MDD-ASCVD.**

1081 (a) Enrichment for the MDD-ASCVD GWAS SNPs in genome-wide significant SNPs for traits in the GWAS catalog  
1082 computed using FUMA. The traits are as reported in the original study. Note that sleep duration here is a  
1083 dichotomization of self-reported sleep. Full name in GWAS catalog of the trait “Coronary artery disease\*” is  
1084 “Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery  
1085 bypass grafting, angina or chronic ischemic heart disease)”. The dashed black line indicates the significance  
1086 threshold after Benjamini-Hochberg adjustment. Adjustment for multiple testing was conducted over all traits in the  
1087 GWAS catalog (>3500 traits). (b) The five SNPs that were significantly associated with MDD-ASCVD, but not with  
1088 any of the constituent traits, with their *P*-value in the GWAS of the constituent traits. The dashed line indicates the  
1089 genome-wide significance threshold ( $P < 5e-8$ ). (c) Genetic correlation of PHQ-9 MDD symptoms with MDD, and  
1090 MDD-ASCVD, with bars representing 95% confidence intervals. Results are based on LD Score Regression analysis.  
1091 (d) Genetic correlation of MDD, MDD-ASCVD, and ASCVD with five psychiatric disorders, with bars representing  
1092 95% confidence intervals. Results are based on LD Score Regression analysis.  
1093 ADHD = Attention Deficit and Hyperactivity Disorder; PTSD = Posttraumatic Stress Disorder.  
1094  
1095




1096

**Extended Data Fig. 5 | Genetic correlation between CVD and risk factors**

Results are based on LD Score Regression analysis. Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. Open dots indicate a non-significant genetic correlation.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein




1097

### Extended Data Fig. 6 | Genetic correlation between MDD traits and risk factors

Results are based on LD Score Regression analysis. Points and error bars represent correlations and 95% CIs. Sample sizes for GWAS summary statistics are reported in Supplementary Table 1. Open dots indicate a non-significant genetic correlation.

MDD=Major Depressive Disorder; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein




1098

### Extended Data Fig 7 | Local genetic correlations between MDD and risk factors.

Volcano plots based on LAVA results. Local genetic correlation between MDD and each of the risk factors (x-axis) and the corresponding  $-\log_{10}$  transformed  $P$ -value (y-axis). Correlations were estimated in the loci that showed marginally significant local heritability in 2,495 considered genomic regions. Loci exceeding the horizontal line are significant at  $P_{FDR} < .05$ . Multiple testing was adjusted for individually for each trait over considered loci.

Psychosocial=Psychosocial/Lifestyle; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein





1099



**Extended Data Fig. 8 | Genetic correlation between MDD and CVD when adjusting for individual risk factors**

Results from Genomic SEM. Bars represent 95% confidence intervals. Reference estimates of the association without any adjustment are printed in black.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein

1100


1101



**Extended Data Fig. 9 | Assessment of evidence for causal associations between MDD, CVD, and risk factors.**

Results from univariable and multivariable Mendelian randomization (MR) analysis (Inverse variance weighted estimates are shown) **(a)** Effect of liability to MDD (exposure) on CVD and risk factors (outcomes) after excluding the UKB sample from MDD (which was responsible for most of the sample overlap in the exposure and outcome GWAS summary statistics). **(b)** Estimated effect of CVD and risk factors on MDD after excluding the UKB. **(c)** Results from LHC-MR, that corrects for heritable confounders and sample overlap, with the standard inverse variance weighted MR estimate given as reference, for the effect of MDD on CVD and risk factors. **(d)** Effect of liability to MDD-ASCVD on outcomes and risk factors. **A-c** Statistically significant pleiotropic estimates are indicated with a red asterisk. The term beta refers to the log odds ratio.

Psychosocial=Psychosocial/Lifestyle; AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein



1104

**Extended Data Fig. 10 | Effects of liability to MDD on CVDs when adjusting for individual risk factors**

Results from multivariable Mendelian randomization. Bars represent 95% confidence intervals. Reference estimates of the association without any adjustment are printed in black.

AF=Atrial Fibrillation; CAD=Coronary Artery Disease; HF=Heart Failure; PAD=Peripheral Artery Disease; DBP=Diastolic Blood Pressure; SBP=Systolic Blood Pressure; PP=Pulse Pressure; Edu=Educational attainment; Phys. Act.=Physical activity; Child. Mal.=Childhood Maltreatment; T2D=Type II Diabetes; TG=Triglycerides; HDL=High-Density Lipoprotein; NonHDL=Non-High-Density Lipoprotein; TC=Total Cholesterol; LDL=Low-Density Lipoprotein; IL6=Interleukin-6; CRP=C-Reactive Protein